Abstract: The present invention relates to the use of a pyrrole compound in the treatment of tumors. Specifically, provided in the present invention is the use of a compound of formula I, or an optical isomer, or a racemate, or a solvate, or a pharmaceutically acceptable salt or a deuterated compound thereof in the preparation of a composition or preparation, wherein the composition or preparation is used for preventing and/or treating tumors. The compound of the present invention has more significantly excellent therapeutic effects on tumors with low or no expression of NNMT genes, high expression of DNA methylase, high expression of UHRF1, high methylation levels at the nucleotide site of NNMT genes and/or high methylation levels at the DNA CpG site in NNMT gene regions.

Abstract: The present invention relates to an application of a benzanilide compound in tumor treatment. Specifically, the present invention provides a use of a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof in the preparation of a composition or a preparation, the composition or the preparation being used for preventing and/or treating tumors. The compound of the present invention has more remarkable and excellent treatment effects on tumors having low or no expression of an NNMT gene, high expression of a DNA methylase, high expression of UHRF1, high methylation level at an NNMT gene nucleotide site, and/or high methylation level at a DNA CpG site in an NNMT gene region.

Abstract: The present invention relates to an application of a hydrazide compound in tumor treatment, and, in particular, the present invention provides a use of a compound represented by formula I, an optical isomer or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, being used for the preparation of a composition or formulation, said composition or formulation being used for the prevention and/or treatment of tumors. The compound of the present invention has significant and exceptional therapeutic effects on tumors having low or no expression of the NNMT gene, high expression of DNA methylase, high expression of UHRF1, high methylation level at the NNMT gene nucleotide site, and/or high methylation level at a DNA CpG site in the NNMT gene region.

Abstract: The present invention relates to an application of a benzisoquinoline diketone compound in the treatment of a tumor. Specifically, the present invention provides a use of a compound of formula (I), or an optical isomer or racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof, or a deuterated compound thereof, i.e., a use in the preparation of a composition or preparation, the composition or preparation being used for preventing and/or treating a tumor. The compound of the present invention has significant and excellent therapeutic effects on tumors having low or no expression of an NNMT gene, high expression of a DNA methylase, high expression of UHRF1, a high methylation level at a nucleotide site of the NNMT gene, and/or a high methylation level at a DNA CpG site of an NNMT gene region.

Abstract: The present invention relates to a benzene ring compound and a use thereof. In particular, provided is a compound as shown in formula I, or an optical isomer thereof or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an application of an isoquinoline compound in tumor treatment. Specifically, the present invention provides a use of a compound of formula I, or an optical isomer or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof used for the preparation of a composition or formulation for the prevention and/or treatment of a tumor. The compound of the present invention has significant and exceptional therapeutic effects on tumors with low or no expression of an NNMT gene, high expression of a DNA methylase, high expression of UHRF1, high methylation levels at an NNMT gene nucleotide site, and/or high methylation levels at a DNA CpG site in an NNMT gene region.

Abstract: The present invention relates to a marker for determining anti-cancer effects of a mitochondrial oxidative phosphorylation pathway inhibitor. Specifically, the present invention relates to use of the mitochondrial oxidative phosphorylation pathway inhibitor for preparing a composition or a formulation for preventing and/or treating tumors. The present invention has found that the mitochondrial oxidative phosphorylation pathway inhibitor has significantly excellent treatment effects on tumors having mitochondrial oxidative phosphorylation pathway up-regulation, low or no expression of an NNMT gene, high expression of a DNA methylase, high expression of UHRF1, a high methylation level of a nucleotide site of an NNMT gene and/or a high methylation level of a DNA CpG site of an NNMT gene region.

Abstract: Provided are scutellariae radix compounds and the use thereof for inhibiting the oxidative phosphorylation pathway of mitochondria. Specifically provided is the use of a compound of formula I, or an optical isomer thereof, or a racemate thereof, or a solvate thereof, or a pharmaceutically acceptable salt thereof in the preparation of a composition or a preparation. The composition or the preparation is used for one or more uses selected from the group consisting of: (a) inhibiting the oxidative phosphorylation pathway of mitochondria; (b) preventing and/or treating diseases associated with the oxidative phosphorylation pathway of mitochondria; and (c) preventing and/or treating cancers.